Conv. Plasma
Nigella Sativa
Peg.. Lambda

All vitamin C studies
Meta analysis
Home COVID-19 treatment researchVitamin CVitamin C (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 13% Improvement Relative Risk Vitamin C  Pourhoseingholi et al.  LATE TREATMENT Is late treatment with vitamin C beneficial for COVID-19? Prospective study of 2,468 patients in Iran (Feb - Jul 2020) Lower mortality with vitamin C (not stat. sig., p=0.38) Pourhoseingholi et al., Research Square, May 2021 Favors vitamin C Favors control

Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study

Pourhoseingholi et al., Research Square, doi:10.21203/
May 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Prospective study of 2,468 hospitalized COVID-19 patients in Iran, showing no significant difference with vitamin C treatment. IR.MUQ.REC.1399.013.
Although the 13% lower mortality is not statistically significant, it is consistent with the significant 20% lower mortality [10‑29%] from meta analysis of the 38 mortality results to date.
This is the 27th of 64 COVID-19 controlled studies for vitamin C, which collectively show efficacy with p=0.00000022. 17 studies are RCTs, which show efficacy with p=0.00000014.
This study includes remdesivir, N-acetylcysteine, aspirin, and vitamin C.
risk of death, 13.0% lower, HR 0.87, p = 0.38, treatment 54 of 199 (27.1%), control 285 of 2,269 (12.6%), adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pourhoseingholi et al., 26 May 2021, prospective, Iran, preprint, mean age 57.9, 11 authors, study period 2 February, 2020 - 20 July, 2020, average treatment delay 7.4 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Case Characteristics, Clinical Data, And Outcomes of Hospitalized COVID-19 Patients In Qom Province, Iran: A Prospective Cohort Study
Mohamad Amin Pourhoseingholi, Hosein Yousefi, Hassan Fatemi Manesh, Nima Najafian Motahaver, Zahra Heydari, Mehdi Azizmohammad Looha, Nazanin Taraghikhah, Maryam Yazdi, Zahra Salami, Elmira Moallemi, Seyed Hasan Adeli
The outbreak of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) dates back to December 2019 in China. Iran has been one of the most virus in icted countries. The aim of this study was to report demographics, signs and symptoms, laboratory ndings, therapeutic approaches, and outcomes. This observational cohort study was performed from 20 th February 2020 to 20 th July 2020. Patients' information was recorded in their medical les. Multivariable analysis was performed to assess demographics, signs and symptoms, paraclinical data, treatments, outcomes of disease, and nding the risk factors of death subject to COVID-19. Of all 2468 participants, the mean age was 57.9±17.6 years and 56.8% of patients were male. The most signi cant comorbidities were seen among those who have Hypertension and Diabetes Mellitus. 14.42% were admitted to ICU, and 17.2% died in hospital. The signi cant risk factors of death were ageing, male gender, HTN, CHF, CVA, CKD, increasing ESR, PT, WBC, liver function tests, and decreasing Oxygen saturation. Incontinent results in the case of COVID-19 outcomes and deathrelated risk factors attribute to marked differences in demographics and health care systems. The patients with hazardous risk factors must be detected urgently and monitored closely to save more lives.
Supplementary Files This is a list of supplementary les associated with this preprint. Click to download. app.docx
Aggarwal, Lippi, Henry, Cerebrovascular disease is associated with an increased disease severity in patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature, International Journal of Stroke
Arab-Mazar, Sah, Rabaan, Mapping the incidence of the COVID-19 hotspot in Iran-Implications for Travellers, Travel Medicine and Infectious Disease
Arentz, Yim, Klaff, Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State, JAMA
Ashraf, Shokouhi, Shirali, COVID-19 in Iran, a comprehensive investigation from exposure to treatment outcomes
Audit, ICNARC report on COVID-19 in critical care
Covid, coronavirus pandemic
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study, The Lancet
Docherty, Harrison, Green, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Duan, Liu, Li, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proceedings of the National Academy of Sciences
Geleris, Sun, Platt, Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19, N Engl J Med
Giacomo, Antonio, Cecconi, Critical care utilization for the COVID-19 outbreak in
Grasselli, Zangrillo, Zanella, Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region
Guan, Ni, Hu, Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med
Karagiannidis, Mostert, Hentschker, Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study, The Lancet Respiratory Medicine
Keith, Day, Choe, The successful use of therapeutic plasma exchange for severe COVID-19 acute respiratory distress syndrome with multiple organ failure, SAGE open medical case reports
Khoshnood, Ommi, Zali, Epidemiological Characteristics, Clinical Features, and Outcome of COVID-19 Patients in Northern Tehran, Iran; a Cross-Sectional Study, Advanced Journal of Emergency Medicine
Nile, Nile, Qiu, COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons, Cytokine Growth Factor Rev
Novel, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua liu xing bing, xue za zhi= Zhonghua liuxingbingxue zazhi
Ranucci, Ballotta, Dedda, The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area
Wang, Fish, Editors, Global virus outbreaks: Interferons as 1st responders, Seminars in immunology
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, Jama
Yang, Yu, Xu, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med
Ye, Fu, Ren, Treatment with convalescent plasma for COVID-19 patients in Wuhan, China, J Med Virol
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zhu, Zhang, Wang, A Novel Coronavirus from Patients with Pneumonia in China, 2019, N Engl J Med
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop